Asparaginase and MOPP Treatment of Dogs with Lymphoma
Open Access
- 1 May 2009
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 23 (3) , 578-584
Abstract
Background: Dogs with multicentric lymphoma are treated with various cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy protocols with variable success. Objectives: To describe the progression-free survival (PFS) time and overall survival time (OST) of dogs with T-cell lymphoma or hypercalcemic lymphoma treated with l-asparaginase and mechlorethamine, vincristine, prednisone, procarbazine (MOPP). Animals: Fifty dogs with T-cell lymphoma, hypercalcemic lymphoma, or both treated at 3 referral veterinary hospitals. Methods: Retrospective study. Case were selected based on histologic or cytologic diagnosis of lymphoma; presence of the T-cell phenotype, presence of hypercalcemia or both; and absence of previous chemotherapy. The T-cell phenotype was determined by flow cytometry, immunocytochemistry, immunohistochemistry, or polymerase chain reaction of antigen receptor rearrangement. Results: The overall response rate was 98% (78% complete response, 20% partial response). The median PFS for the entire study population was 189 days with 25% PFS at 939 days. The median OST for the entire study population was 270 days with 25% surviving 939 days. Twenty percent of the dogs required hospitalization for treatment related complications. Conclusions and clinical importance: l-Asp/MOPP chemotherapy might result in longer PFS and OST for dogs with multicentric T-cell lymphoma, dogs with hypercalcemic lymphoma or both, than achieved with CHOP.Keywords
This publication has 20 references indexed in Scilit:
- Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD moleculesVeterinary Immunology and Immunopathology, 2005
- Veterinary co‐operative oncology group – common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0Veterinary and Comparative Oncology, 2004
- Chemotherapy Followed by Half-Body Radiation Therapy for Canine LymphomaJournal of Veterinary Internal Medicine, 2004
- Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2002
- Evaluation of a High-Dose Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2000
- Prognostic Factors in Dogs with Lymphoma and Associated HypercalcemiaJournal of Veterinary Internal Medicine, 1991
- British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease – long term resultsBritish Journal of Cancer, 1991
- Lymphomas in dogs a morphologic, immunologic, and clinical studyCancer, 1990
- Twenty years of MOPP therapy for Hodgkin's disease.Journal of Clinical Oncology, 1986
- Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapyHematological Oncology, 1984